LAB standard Biotools announces sale of mass cytometry business and illumina’s buyout of contingent payments to advance merger with treeline
LAB standard Biotools announces sale of mass cytometry business and illumina’s buyout of contingent payments to advance merger with treeline Biosciences Standard Biotools - to sell mass cytometry business to multiplex Bio - Mass cytometry business sale valued at up to $10M
Story updates
12:02:19 PM UTC
SquawkNews
LAB - Standard BioTools Announces Sale of Mass Cytometry Business and Illumina’s Buyout of Contingent Payments to Advance Merger with Treeline Biosciences
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.